In the current study, we investigated the relationship between NAFLD phenotype and treatment response on levels of serum HMGB1 in adults and children participating in PIVENS and TONIC clinical trials. This evidence concerns the gene HMGB1 and metabolic dysfunction-associated steatotic liver disease.